KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

被引：0

作者：

Galsky, M. ^{[1
]}

Necchi, A. ^{[2
]}

Shore, N. D. ^{[3
]}

Witjes, F. ^{[4
]}

Nam, K. ^{[5
]}

Godwin, J. L. ^{[5
]}

Frenkl, T. L. ^{[5
]}

Plimack, E. R. ^{[6
]}

机构：

[1] Mt Sinai Hosp, Icahn Sch Med, Tisch Canc Inst, New York, NY 10029 USA

[2] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[3] Carolina Urol Res Ctr, Med Oncol, Myrtle Beach, SC USA

[4] Radboudumc, Urol, Nijmegen, Netherlands

[5] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[6] Fox Chase Canc Ctr, Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

989TiP

引用

页数：1

共 50 条

[1] Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905
Galsky, Matt D.
Necchi, Andrea
Shore, Neal D.
Witjes, Fred
Nam, Kijoeng
Sbar, Eric
Moreno, Blanca Homet
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[2] KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
Galsky, Matt D.
Necchi, Andrea
Shore, Neal D.
Plimack, Elizabeth R.
Jia, Calvin
Sbar, Eric
Moreno, Blanca Homet
Witjes, Johannes Alfred
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[3] KEYNOTE-905/EV-303: A phase 3 study of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer
Hennika, Tammy
Galsky, Matthew D.
Necchi, Andrea
Shore, Neal D.
Plimack, Elizabeth
Jia, Calvin
Moreno, Blanca Homet
Witjes, J. Alfred
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 207 - 208
[4] Perioperative Use of Pembrolizumab in muscle-invasive Bladder Cancer A randomized Phase 3 Trial evaluating Cystectomy combined with perioperative Administration of Pembrolizumab versus Cystectomy alone in Study Participants with muscle-invasive Bladder Cancer who are not eligible for Cisplatin Treatment (KEYNOTE-905) - AB 71/ 19 of AUO
Rexer, H.
Bedke, J.
Merseburger, A.
AKTUELLE UROLOGIE, 2020, 51 (05) : 418 - 420
[5] Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303
Necchi, A.
Bedke, J.
Galsky, M. D.
Shore, N. D.
Xylinas, E.
Jia, C.
Dubrovsky, L.
Homet, Moreno B.
Witjes, A. J.
EUROPEAN UROLOGY, 2023, 83 : S751 - S751
[6] Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303
Galsky, Matthew D.
Hoimes, Christopher J.
Necchi, Andrea
Shore, Neal
Witjes, J. Alfred
Steinberg, Gary
Bedke, Jens
Nishiyama, Hiroyuki
Fang, Xiao
Kataria, Ritesh
Sbar, Eric
Jia, Xieyang
Siefker-Radtke, Arlene
FUTURE ONCOLOGY, 2021, 17 (24) : 3137 - 3150
[7] Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.
Balar, Arjun Vasant
James, Nicholas D.
Shariat, Shahrokh F.
Shore, Neal D.
Van der Heijden, Michiel Simon
Weickhardt, Andrew James
Fang, Xiao
Godwin, James Luke
Kapadia, Ekta
Michalski, Jeff M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
Necchi, Andrea
Bedke, Jens
Galsky, Matt D.
Shore, Neal D.
Plimack, Elizabeth R.
Xylinas, Evanguelos
Jia, Calvin
Hennika, Tammy
Moreno, Blanca Homet
Witjes, Alfred Alfred
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[9] KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
Necchi, Andrea
Bedke, Jens
Galsky, Matt D.
Shore, Neal D.
Xylinas, Evanguelos
Jia, Calvin
Dubrovsky, Leonid
Moreno, Blanca Homet
Witjes, J. Alfred
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)
Siefker-Radtke, A. O.
Steinberg, G.
Bedke, J.
Nishiyama, H.
Martin, J.
Kataria, R.
Frenkl, T. L.
Hoimes, C. J.
ANNALS OF ONCOLOGY, 2019, 30 : 401 - 401

← 1 2 3 4 5 →